Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma-Reference-Cited by-同舟云学术

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

Published:2022-09-02 Issue:3 Volume:12 Page:2761-2771
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Matsubara Nobuaki¹^ORCID,Yonese Junji²,Kojima Takahiro³,Azuma Haruhito⁴,Matsumoto Hiroaki⁵,Powles Thomas⁶,Rosenberg Jonathan E.⁷,Petrylak Daniel P.⁸,Matsangou Maria⁹,Wu Chunzhang⁹,Campbell Mary¹⁰,Yamashiro Mayumi¹¹

Affiliation:

1. Department of Medical Oncology National Cancer Center Hospital East Chiba Japan

2. Department of Urology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan

3. Department of Urology Aichi Cancer Center Nagoya Aichi Japan

4. Department of Urology Osaka Medical and Pharmaceutical University Osaka Japan

5. Department of Urology Yamaguchi University, School of Medicine Ube Japan

6. Barts Cancer Institute, CRUK Experimental Cancer Medicine Centre London UK

7. Department of Medicine, Division of Solid Tumor Oncology Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center New York New York USA

8. Yale Cancer Center New Haven Connecticut USA

9. Astellas Pharma, Inc. Northbrook Illinois USA

10. Seagen Inc. Bothell Washington USA

11. Astellas Pharma, Inc. Tokyo Japan

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5165

Reference32 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries